You can legally receive a GLP-1 prescription — for Ozempic, Wegovy, Mounjaro, or Zepbound — through a telehealth platform without an in-person visit in most U.S. states. Platforms vary significantly in cost, which medications they offer, whether they use brand-name or compounded versions, and how closely they monitor your progress. Here is what to know before choosing one.

What Makes a GLP-1 Telehealth Platform Legitimate?

A legitimate platform must connect you with a licensed, U.S.-based prescriber — a physician, nurse practitioner, or physician assistant — who reviews your health history before writing any prescription. Per FDA labeling for Wegovy and Zepbound, prescribers are expected to evaluate BMI, weight-related comorbidities, and contraindications such as a personal or family history of medullary thyroid carcinoma.

  • Prescriber credentials: Confirm the platform employs licensed clinicians in your state.
  • Medication source: Branded FDA-approved drugs should come from licensed pharmacies. Compounded semaglutide or tirzepatide carries additional regulatory caveats (see below).
  • Ongoing monitoring: Reputable services schedule follow-up visits and dose escalation check-ins.
  • Transparent pricing: Total cost — consultation, medication, and any required lab work — should be disclosed upfront.
  • No guarantees: Any platform promising specific weight-loss results violates FTC guidelines. The FTC took action in 2024 against companies making unsupported weight-loss drug claims.

How Do the Top Platforms Compare?

The table below reflects publicly available pricing and policies as of mid-2025. Costs change frequently — always verify directly with the platform before signing up.

Platform Medications Offered Approx. Monthly Cost Branded or Compounded Insurance Accepted Follow-Up Care
Hims & Hers Compounded semaglutide ~$199–$299 Compounded No Messaging + check-ins
Ro Body Wegovy, compounded semaglutide ~$99 program fee + Rx cost Both Limited Coaching + provider access
Noom Med Wegovy, Ozempic, Zepbound ~$149–$199 + Rx cost Branded Yes (some plans) Behavioral coaching included
WeightWatchers Clinic Wegovy, Zepbound, Ozempic ~$99/mo + Rx cost Branded Yes (some plans) Structured program
Found Ozempic, Wegovy, Mounjaro, Zepbound ~$99/mo + Rx cost Branded Yes (some plans) Health coach + provider
Calibrate Ozempic, Wegovy, Mounjaro, Zepbound ~$199/mo (program) Branded Helps with submission Metabolic coaching

Most important point: Compounded semaglutide and tirzepatide are not FDA-approved drugs. The FDA has confirmed that semaglutide and tirzepatide are no longer on the shortage list as of early 2025, which means most compounded versions are no longer legally permitted under federal rules. If a platform is still offering compounded versions, ask specifically about their pharmacy's compliance status before proceeding.

What Is the Typical Onboarding Process?

Most platforms follow a similar intake sequence, though timelines vary. The week-by-week breakdown below reflects a typical experience:

Week What Happens
Week 1 Complete intake questionnaire: medical history, current medications, BMI, goals. Pay consultation fee.
Week 1–2 Async or video review by a licensed prescriber. Lab work may be requested (A1C, lipids, metabolic panel).
Week 2–3 Prescription sent to in-network or mail-order pharmacy. Starting dose is typically the lowest labeled dose.
Week 4–5 First follow-up check-in. Side effects reviewed. Dose escalation scheduled per FDA-labeled titration schedule.
Month 3+ Ongoing monthly or quarterly provider visits. Insurance prior authorization support on many platforms.

What About Insurance and Cost?

Branded GLP-1 medications are expensive without coverage. The list price for Wegovy is approximately $1,349 per month, and Zepbound is approximately $1,059 per month, according to manufacturer published pricing. Most commercial insurers cover these drugs only for qualifying diagnoses — obesity (BMI ≥30 or ≥27 with a comorbidity) for Wegovy and Zepbound, or type 2 diabetes for Ozempic and Mounjaro.

  • Manufacturer savings programs: Novo Nordisk and Eli Lilly both offer savings cards that can reduce out-of-pocket costs to as low as $25/month for eligible commercially insured patients.
  • Prior authorization: Most insurers require it. Platforms like Noom Med, Found, and Calibrate assist with PA paperwork.
  • Medicare and Medicaid: Medicare Part D currently does not cover weight-loss drugs, though coverage for Wegovy for cardiovascular risk reduction is expanding following the 2023 SELECT trial results.
  • Self-pay: If paying out of pocket, ask your prescriber about GoodRx or Cost Plus Drugs pricing for Ozempic, which is sometimes lower than the list price.

What Are the Eligibility Requirements?

FDA labeling sets the minimum clinical thresholds that any legitimate prescriber — telehealth or in-person — must follow. According to FDA prescribing information:

  • Wegovy and Zepbound: Adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
  • Ozempic: Adults with type 2 diabetes to improve glycemic control.
  • Mounjaro: Adults with type 2 diabetes as an adjunct to diet and exercise.
  • Universal contraindications: Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Platforms that skip these questions or approve everyone automatically are a red flag. A 2021 NEJM study (Wilding et al.) confirming semaglutide's efficacy enrolled participants who met these same clinical criteria — the labeled thresholds exist for safety reasons, not as arbitrary gatekeeping.

Frequently Asked Questions

It can be safe when a licensed prescriber conducts a thorough intake and review. The key is whether the platform actually evaluates your full health history — including contraindications listed in FDA labeling — and provides ongoing monitoring. Telehealth expansions from HHS have made async and video prescribing legal in most states.
Yes. Platforms like Found, Noom Med, WeightWatchers Clinic, and Calibrate prescribe FDA-approved branded medications sent to licensed pharmacies. Some platforms also offered compounded versions during the shortage period, but with both semaglutide and tirzepatide removed from the FDA shortage list in 2025, compounded versions face significant legal restrictions.
Reputable platforms follow the FDA-labeled titration schedules — for example, Wegovy starts at 0.25 mg weekly and increases every four weeks up to the 2.4 mg maintenance dose. A provider check-in before each dose increase is standard practice on better platforms. Rapid or unsupervised escalation increases the risk of gastrointestinal side effects.
Coverage depends on your specific plan, not on whether the prescription came from telehealth or an in-person visit. What matters to insurers is the diagnosis code, the medication, and whether prior authorization criteria are met. Many telehealth platforms assist with prior authorization submissions, but approval is ultimately your insurer's decision.
Avoid any platform that: approves everyone instantly without a medical review, makes specific weight-loss guarantees (an FTC violation), does not disclose prescriber credentials, ships medication before you speak with or message a clinician, or offers compounded semaglutide/tirzepatide without addressing the current FDA shortage-list status.
Not always, but it is often recommended. For type 2 diabetes indications, an A1C is typically required. For obesity indications, a metabolic panel and lipid panel help the prescriber assess baseline health. Some platforms require recent labs; others allow you to proceed and submit labs within a few weeks of starting.
Yes. You can transition your GLP-1 prescription to any licensed prescriber, including your primary care physician or an endocrinologist. Ask the telehealth platform for a visit summary and medication history to share with your new provider. Continuity of care is important for safe dose management.

Choosing the right telehealth platform for a GLP-1 prescription is a meaningful medical decision, not just a shopping exercise. Before signing up with any service, review their prescriber credentials, understand exactly what medication they are providing and from which pharmacy, confirm how dose escalation is managed, and get a full breakdown of costs including the medication itself. Your prescriber — whether reached through telehealth or in person — is your best resource for determining which GLP-1 medication fits your specific health profile, insurance situation, and treatment goals.

Sources
  • FDA. Ozempic (semaglutide) Prescribing Information
  • FDA. Wegovy (semaglutide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
  • FDA. Zepbound (tirzepatide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  • Joshi SS, et al. 'Telemedicine in the Era of COVID-19.' Journal of Allergy and Clinical Immunology: In Practice. 2020.
  • Wilding JPH, et al. 'Once-Weekly Semaglutide in Adults with Overweight or Obesity.' NEJM. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  • FTC. 'FTC Takes Action Against Companies Claiming to Sell Wegovy.' 2024
  • HRSA Telehealth. 'Telehealth Policy.' https://telehealth.hhs.gov/providers/policy-changes-during-covid-19/prescribing-controlled-substances-via-telehealth

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.